Quantitative clinical pharmacology is transforming drug regulation

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 6, 2010, Pages 617-628

  Peck, Carl C ^a  

^a NONE

Author keywords

Drug development; Drug regulation; Quantitative clinical pharmacology; Regulatory science

Indexed keywords

DIGOXIN; GENERIC DRUG; KETOCONAZOLE; NEW DRUG; RETINOIC ACID; TERFENADINE;

BIOEQUIVALENCE; CARDIOTOXICITY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG METABOLISM; DRUG MICRODOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG REGULATION; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSPORT; EMPIRICISM; ENZYME METABOLISM; FOOD AND DRUG ADMINISTRATION; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; TERATOGENICITY;

ANIMALS; DRUG APPROVAL; DRUG EVALUATION; DRUG INTERACTIONS; GOVERNMENT AGENCIES; HUMANS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; TECHNOLOGY TRANSFER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79951762943     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9171-3     Document Type: Conference Paper

References (89)

1. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497 (Pubitemid 41127293)
2. Urquhart J, Vrijens B (2005) New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hosp Pharm Sci 11:103-106
3. Kenna LA, Sheiner LB (2004) Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods. Stat Med 23:3561-3580 (Pubitemid 39549563)
4. Benet L, Rowland M (1982) Pharmacometrics: a new journal section. J Pharmaocokin Biopharm 10:349-350
5. Bacharach AL, Laurence DR (1964) Evaluation of drug activities: pharmacometrics, vol 1. Academic Press, New York
6. Steimer JL, Sheiner LB (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95 (Pubitemid 30340674)
7. Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligan SRB (2006) Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33:567-1567
8. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82:21-32 (Pubitemid 46950619)
9. Blackstone MO, Lindenbaum J, Buler VP (1971) Variations in biological availability of digoxin from four preparations. N Engl J Med 285:1344
10. 21 C.F.R. (1977) § 320 Bioavailability and bioequivalance requirements. Fed Regist 42:1648
11. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well- stirred " model and a "parallel tube " model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokin Biopharm 5:625-653 (Pubitemid 8253670)
12. Roberts MS, Rowland M (1977) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokin Biopharm 14
13. Benet LZ, Rowland M, Graham GG (1973) Hepatic clearance of drugs. I. Theoretical considerations of a "well stirred " model and a "parallel tube " model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Pharmacodyn 1:123-136
14. Beal SL, Sheiner LB, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmackinet Pharmacodyn 5:445-479 (Pubitemid 8224518)
15. Food and Drug Administration (1989) Guideline for the study of drugs likely to be used in the elderly
16. Peck C, Collins J, Barr W, Benet L, Desjardins R, Furst D, Harter JG, Levy G, Ludden T, Rodman J, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J, Yacobi A (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 51:465-473
17. Sanathanan LP, Peck CC (1991) The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control Clin Trials 12:780-794
18. Peck CC (1992) Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Conference on new strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities: European cooperation in the field of scientific and technical research, pp 157-168
19. Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics
20. Hale MD, Gillespie WR, Gupta SK, Tuck B, Holford NH (1996) Clinical trial simulation: streamlining your drug development process. Appl Clin Trials 5:35-40 (Pubitemid 126109089)
21. Monteleone JPR, Holford NHG, Kimko HC, Peck CC (2000) Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40:209-234 (Pubitemid 30340680)
22. Lesko L, Williams RL (1999) The question-based review-a conceptual framework for good review practices. Appl Clin Trials 56-62
23. Food and Drug Administration (2003) Concept paper End-of-Phase-2A meetings with sponsors regarding exposure-response and IND and NDA products
24. Food and Drug Administration (2008) Guidance for industry End-of-Phase 2A meetings
25. Pharmacometrics at FDA (2009) http://www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm167032.htm
26. 21 C.F.R. (1977) § 320 Part 25 guidelines for the conduct of an in vivo bioavailability study. Fed Regist 42:1648
27. Food and Drug Administration (2003) Guidance for industry clinical bioavailability and bioequiv- alence studies for orally administered drug products-general considerations. http://www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
28. Food and Drug Administration (1994) Guidance for industry: dose-response information to support drug registration
29. Food and Drug Administration (2003) Guidance for industry exposure-response relationships-study design, data analysis, and regulatory applications
30. Peck C, Temple R, Collins J (1973) Understanding consequences of concurrent therapies. JAMA 269:1550-1552
31. Banfield C, O'Reilly RE, Chan E, Rowland M (1983) Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 16:669-675 (Pubitemid 14208205)
32. Rowland M, Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokin Biopharm 1:553-568
33. Food and Drug Administration (1999) Guidance for industry in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling
34. Food and Drug Administration (2006) Guidance for industry drug interaction studies-study design, data analysis, and implications for dosing and labeling
35. Food and Drug Administration (1997) Guidance for industry in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling
36. Jeffords AJM (1997) Clarification of the number of required clinical investigations for approval. Report 105-43 of U. S. Senate Committee on Labor and Human Resources on the Food and Drug Administration Modernization Act of 1997, pp 30-31
37. Food and Drug Administration Modernization Act of 1997 (1997)
38. Jeffords AJM (1997) Pediatric studies of drugs. Report 105-43 of U. S. Senate Committee on Labor and Human Resources on the Food and Drug Administration Modernization Act of 1997, pp 51-52
39. Bliley TJ (1997) Report 105-310 of the U. S. House Committee on Commerce Report on the Prescription Drug User Fee Reauthorization and Drug Regulatory Modernization Act of 1997, pp 67-68
40. Food and Drug Administration (1998) Guidance for industry providing evidence of effectiveness for human drug and biological products
41. Peck CC, Wechsler J (2002) Report of a workshop on confirmatory evidence to support a single clinical trial for new drug approval. Drug Inf J 36:517-534
42. Benowitz N, Forsyth RP, Melmon KL, Rowland M (1974) Lidocaine disposition kinetics in monkey and manI. Prediction by a perfusion model. Clin Pharmacol Ther 16:87-98
43. Blakey GM, Nestorov IA, Arundel PA, Aarons LJ, Rowland M (1997) Quantitative structure- pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in the pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokin Biopharm 25:277-312 (Pubitemid 28045711)
44. Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918-933 (Pubitemid 46675393)
45. Rodgers T, Leahy E, Rowland M (2005) Physiologically-based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276 (Pubitemid 40904190)
46. Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148 (Pubitemid 46745341)
47. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133
48. Clewell HJ, Andersen ME, Wills RJ, Latriano L (1997) A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77-S85 (Pubitemid 27132004)
49. Ghosh TK (2000) Clinical pharmacology and biopharmaceutics review: NDA 21-108 0.02% Tretinoin Emollient Cream (RENOVA®). http:// wwwaccessdatafdagov/drugsatfda-docs/nda/2000/21- 108-Renova-BioPharmrpdf,p19
50. Balant L, Rowland M, Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. AAPS J 6:6-10
51. Oo C, Chen YC (2009) The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol 49:368-369
52. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang S-M (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351-359
53. Peck C, Rowland M, Tucker G (2011) Physiologically based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73
54. Huang W, Lee SL, Yu LX (2009) Mechanistic approaches to predicting oral drug absorption. AAPS J 11:217-224
55. Huang S-M, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670 (Pubitemid 351713150)
56. Huang S-M, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, Lesko LJ (2010) Therapeutic proteindrug interactions and implications for drug development. Clin Pharmacol Ther 87:497-503
57. Zhang L, Zhang YD, Zhao P, Huang S-M (2009) Predicting drug-drug interactions: an FDA perspective. AAPS J 11:300-306
58. Zhang L, Reynolds KS, Zhao P, Huang S-M (2010) Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 243:134-145
59. Duan JZ, Jackson AJ, Zhao P (2010, in press) Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J Clin Pharmacol. doi:10.1177/0091270010372387
60. Zhao P, Zhang L, Huang S-M (2010) Complex drug interactions: significance and evaluation. In: Pang KS, Rodrigues AD, Peter RM (eds) Enzyme- and transporter-based drug-drug interactions: progress and future challenges. Springer, New York, 746 pp
61. Food and Drug Administration (2005) Guidance for industry clinical lactation studies-study design, data analysis, and recommendations for labeling. http://www.fda.gov/downloads/RegulatoryInforma tion/Guidances/ucm127505.pdf
62. European Medicines Agency (2008) EMEA workshop on modeling in paediatric medicines. http:// wwwemaeuropaeu/meetings/conferences/1415apr08htm
63. Manolis E, Pons G (2009) Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol 68:493-501
64. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi N, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JVS (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13-18 (Pubitemid 350292272)
65. Garnett C, Lee JY, Gobburu JVS (2011) U.S. FDA perspective: impact of modeling and simulation on regulatory decision making. In: Kimko HC, Peck CC (eds) Clinical trials simulation: applications and trends. Springer
66. Zhu H, Wang Y, Gobburu JV, Garnett CE (2010) Considerations for clinical trial design and data analyses of thorough QT studies using drug-drug interaction. J Clin Pharmacol 50:1106-1111
67. Bhattaram V, Siddiqui O, Kapcala L, Gobburu J (2009) Endpoints and analyses to discern diseasemodifying drug effects in early Parkinson s disease. AAPS J 11:456-464
68. Wang Y, Bhattaram VA, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JVS (2008) Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol 48:146-156
69. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC (2006) Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs[ast]. Clin Pharmacol Ther 80:203-215 (Pubitemid 44313903)
70. Food and Drug Administration (2006) Guidance for industry, investigators, and reviewers exploratory IND studies
71. Goodsaid F, Frueh FW (2007) Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen 48:354-358 (Pubitemid 47011763)
72. Huang SM, Goodsaid F, Rahman A, Fruehand F, Lesko LJ (2006) Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods 16:89-99
73. Sheiner LB (1991) The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 50:4-9
74. Critical Path Initiative. Food and Drug Administration, Center for Drug Evaluation and Research (2006).
75. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275-291 (Pubitemid 27145429)
76. Peck CC, Rubin DB, Sheiner LB (2003) Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther 74:481-490 (Pubitemid 37249119)
77. Doblin RE (2000) Regulation of the medical use of psychedelics and marijuana. PhD, Harvard University, Cambridge
78. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta M, Gobburu JV (2005) Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 7:E503-E512
79. Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, Men Y, Powell JR, Qiu W, Ramchandani RP, Tornoe CW, Wang Y, Zheng JJ (2007) Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 81:213-221 (Pubitemid 46174818)
80. Garnett C, Lee J-Y, Gobburu JVS (2011, in press) U.S. FDA perspective: impact of modeling and simulation on regulatory decision making. In: Clinical trials simulation: applications and trends. Springer
81. Gobburu VS (2010) Pharmacometrics 2020. J Clin Pharmacol 50(9):151S-157S
82. Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DD, Lalonde RL (2005) How modeling and simulation have enhanced decision making in new drug development. J Pharmackinet Pharmacodyn 32:185-197 (Pubitemid 41712739)
83. Olson SC, Bockbrader H, Boyd RA, Cook J, Koup JR, Lalonde RL, Siedlik PH, Powell JR (2000) Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis. Clin Pharmacokinet 38:449-459 (Pubitemid 30265263)
84. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142-152 (Pubitemid 27336953)
85. Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL (2005) How modeling and simulation have enhanced decision making in new drug development 2. J Pharmacokinet Pharmacodyn 32:185-197 (Pubitemid 41712739)
86. Balant L, Rowland M, Peck C (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharm 40:803-814
87. Rowland M, Tozer TN (2006) Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Lippincott, Williams & Wilkins, Baltimore
88. Rowland M, Tozer TN (1980, 1988, 1995, 2011) Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Wolters Kluwer Health, Lippincott, Williams and Wilkins
89. Huang S-M (October 1, 2009) Personal Communication